Focus on Immunodeficiencies: Pharmaceuticals Policy and Law

by Valverde, J. L.; Watters, D.

• ISBN13: 9781586038410
• ISBN10: 1586038419
• Format: Paperback
• Copyright: 2008-02-28
• Publisher: Ios Pr Inc

Summary

Proper treatment and early diagnosis of primary immunodeficiencies is a worldwide public heath priority and therefore the tenth volume of Pharmaceuticals Policy and Law: Focus on Immunodeficiencies focuses on awareness about this issue for the sake of many patients in need. Primary immunodeficiencies in particular are a major public health issue and are still nowadays too often ignored. However, ignoring them is an extremely costly way to handle the issue. Not treating these patients can be an additional burden to the economy or just result in poverty and increased ill-health. Unfortunately, because symptoms of primary immunodeficiencies often manifest as common affections such as pneumonia, bronchitis, or gastroenteritis, without proper knowledge about what causes these symptoms, many doctors focus on treating the symptoms rather than the cause. This leads to a huge waste of healthcare resources as the infections keep coming back and costly and prolonged hospital stays are needed. Proper treatment through immunoglobulin replacement therapy has been shown to significantly reduce episodes of infection, hospital stays and enable affected people to lead normal active professional lives. In order to put an end to this tendency, this volume strives to facilitate the increase of awareness of the issue.

Table of Contents

Introduction and Definition

What are immunodeficiencies?

Living with primary immunodeficiency

Living life to the fullest

Treatment and Care

Treatment options for primary immunodeficiencies

Immunoglobulins: Unique therapies

The role of nurses in recognizing and caring for patients with primary immunodeficiencies

Immunodeficiencies in the EU

Primary immunodeficiencies in Europe

Primary immunodeficiencies in the EU: The physician's perspective

PIDs in the EU: A regulator's perspective of intravenous immunoglobulins (IVIGs)

Action for rare diseases in the European Union

Immunodeficiencies in the EU: Viewpoint from the European Parliament

Immunodeficiencies in the U.S.

Primary immunodeficiency diseases in the United States: The patient perspective

Population prevalence of diagnosed primary immunodeficiency diseases in the United States

Immunodeficiencies and the developing world

Primary immunodeficiencies in India: The patient perspective

Primary immunodeficiencies in Argentina: The patient perspective

Primary immunodeficiency disorders in India: The physician perspective

Pharmacoeconomics

Impact of intravenous immunoglobulin (IVIG) treatment among patients with Primary Immunodeficiency diseases

The value of early diagnosis and treatment of patients with primary antibody deficiencies

Immunodeficiencies tomorrow

Primary Immunodeficiencies (PID): The importance of earliest possible diagnosis

Meeting the global demand for immunoglobulins

Appendices

Core SPC for Human Normal Immunoglobulin for Intravenous Use, CPMP/ BPWG/869/rev 2 of 29 July 2004

Core SPC for Human Normal Immunoglobulin for Subcutaneous and Intramuscular Use, EMEA/CPMP/BPWG/282/00 of 25 July 2002

European Pharmacopoeia 5.3 01/2006:0338, Monograph Human Normal Immunoglobulin

Directive 89/381/EEC of June 1989

Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003

Directive 2004/33/EC of 22 March 2004

Author Index Volume 10 (2008)

Table of Contents provided by Blackwell. All Rights Reserved.